To the Editor The recent meta-analysis published by Jacobsen and colleagues1 in JAMA Dermatology amalgamated all available evidence pertaining the role of vismodegib for locally advanced and metastatic basal cell carcinoma. Well-conducted meta-analyses can provide more accurate estimates of response and safety and investigate further the reasons for clinical discrepancies across studies.2